Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $10 from $13 and keeps an Equal Weight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco price target lowered to $13 from $15 at Stifel
- Elanco Animal Health: Strong Buy Rating Driven by Pet Health Growth and Innovative Products
- Elanco Animal Health Announces Board Changes Amid New Agreement
- Elanco director buys $272.6K in common stock
- Elanco price target lowered to $12 from $16 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue